Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HRTIS.HE
- Price
- 1.47
- Stock movement up
- +0.07 (4.63%)
- Company name
- Herantis Pharma Oyj
- Exchange
- (HE ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Market cap
- 29.64M
- Ent value
- 26.15M
- Price/Sales
- -
- Price/Book
- 6.27
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 1.38%
- 3 year return
- -6.00%
- 5 year return
- -28.01%
- 10 year return
- -14.45%
Last updated: 2025-04-12
DIVIDENDS
HRTIS.HE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 6.27 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 20.16M |
| EPS (TTM) | -0.27 |
| FCF per share (TTM) | -0.17 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -5.88M |
| Net income (TTM) | -5.47M |
| EPS (TTM) | -0.27 |
| EPS (1y forward) | -0.21 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.50M |
| Net receivables | 0.00 |
| Total current assets | 6.75M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 6.75M |
| Accounts payable | 748.67K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.99M |
| Total liabilities | 2.02M |
| Shareholder's equity | 4.73M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -3.36M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -3.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -115.70% |
| Return on Assets | -81.06% |
| Return on Invested Capital | -114.97% |
| Cash Return on Invested Capital | -70.59% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.44 |
| Daily high | 1.50 |
| Daily low | 1.43 |
| Daily Volume | 8K |
| All-time high | 10.59 |
| 1y analyst estimate | 2.20 |
| Beta | 0.31 |
| EPS (TTM) | -0.27 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 24 Apr 2025 |
Downside potential
Loading...
Downside potential data
| HRTIS.HE | S&P500 | |
| Current price drop from All-time high | -86.12% | -12.89% |
| Highest price drop | -92.78% | -56.47% |
| Date of highest drop | 5 Aug 2016 | 9 Mar 2009 |
| Avg drop from high | -62.00% | -11.07% |
| Avg time to new high | 2726 days | 12 days |
| Max time to new high | 2725 days | 1805 days |
COMPANY DETAILS
Marketcap
29.64M
Marketcap category
Small-cap
Description
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.
Employees
11
Website
Investor relations
-
SEC filings
CEO
Country
Finland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Global markets have shown mixed performances recently, with major U.S. indices like the S&P 500 and Nasdaq Composite reaching record highs, while smaller-cap indexes such as the Russell 2000 experienc...
December 11, 2024